Spots Global Cancer Trial Database for PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
Official Title: PD-1 Antibody Combined With Chemoradiotheapy vs. Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients: a Multicenter, Randomised Controlled, Phase III Clinical Trial
Study ID: NCT03907826
Conditions
Study Description
Brief Summary: This is a multicenter, randomized controlled, phase III clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of PD-1 antibody with chemoradiotherapy versus chemoradiotherapy alone in recurrent nasopharyngeal carcinoma patients.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Peking University Third Hospital, Beijing, , China
Sichuan Cancer Hospital, Chengdu, , China
Fujian Province Cancer Hospital, Fuzhou, , China
Guizhou Cancer Hospital, Guiyang, , China
Zhejiang Cancer Hospital, Hangzhou, , China
Jiangxi Cancer Hospital, Nanchang, , China
The First Affiliated Hospital of Guangxi Medical University, Nanning, , China
Fudan University Shanghai Cancer Center, Shanghai, , China
Zhongnan Hospital of Wuhan University, Wuhan, , China
Xijing Hospital, Xi'an, , China
The First Affiliated Hospital of Xiamen University, Xiamen, , China
Contact Details
Name: Chong Zhao
Affiliation: Sun Yat-sen University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
